- Home
- ITRG vs BOLD Comparison
ITRG vs BOLD Comparison
Compare ITRG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- BOLD
- Stock Information
- Founded
- ITRG 1997
- BOLD 2018
- Country
- ITRG Canada
- BOLD United States
- Employees
- ITRG N/A
- BOLD N/A
- Industry
- ITRG Precious Metals
- BOLD
- Sector
- ITRG Basic Materials
- BOLD
- Exchange
- ITRG Nasdaq
- BOLD Nasdaq
- Market Cap
- ITRG 523.9M
- BOLD 33.4M
- IPO Year
- ITRG N/A
- BOLD 2024
- Fundamental
- Price
- ITRG $2.83
- BOLD $1.40
- Analyst Decision
- ITRG Strong Buy
- BOLD Buy
- Analyst Count
- ITRG 2
- BOLD 4
- Target Price
- ITRG $4.00
- BOLD $4.00
- AVG Volume (30 Days)
- ITRG 2.3M
- BOLD 169.9K
- Earning Date
- ITRG 11-12-2025
- BOLD 11-05-2025
- Dividend Yield
- ITRG N/A
- BOLD N/A
- EPS Growth
- ITRG N/A
- BOLD N/A
- EPS
- ITRG 0.09
- BOLD N/A
- Revenue
- ITRG $148,447,000.00
- BOLD N/A
- Revenue This Year
- ITRG $871.24
- BOLD N/A
- Revenue Next Year
- ITRG $2.41
- BOLD N/A
- P/E Ratio
- ITRG $32.76
- BOLD N/A
- Revenue Growth
- ITRG N/A
- BOLD N/A
- 52 Week Low
- ITRG $0.79
- BOLD $1.00
- 52 Week High
- ITRG $3.49
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- ITRG 47.62
- BOLD 56.26
- Support Level
- ITRG $2.64
- BOLD $1.37
- Resistance Level
- ITRG $3.02
- BOLD $1.52
- Average True Range (ATR)
- ITRG 0.19
- BOLD 0.09
- MACD
- ITRG -0.06
- BOLD -0.01
- Stochastic Oscillator
- ITRG 24.14
- BOLD 50.00
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.